Abstract：
Hepatic adenomas (HA), or hepatocellular adenomas, are benign, solid liver lesions that develop in otherwise normal livers, often in the setting of increased estrogen levels. While considered a benign tumor, there is a risk for substantial complications such as hemorrhage and malignant transformation. We review the diagnosis, classification, and potential therapeutic management options for patients with HA.
A scoping narrative review was conducted based on recent literature regarding classification, diagnosis, and management of HA.
While HAs are typically considered benign, complications such as hemorrhage and malignant transformation may occur in approximately 25% and 5% of patients, respectively. Recent advances in imaging and molecular profiling have allowed for the classification of HAs into subtypes allowing for patient risk stratification that helps guide management. Surgical resection should be considered in asymptomatic patients who are male, have an adenoma ≥5 cm in diameter, or have the β-catenin-activated subtype due to an increased risk of hemorrhage and/or malignant transformation.
Molecular profiling has aided in the stratification of patients relative to the risk of complications to predict better the potential behavior of HAs.
A scoping narrative review was conducted based on recent literature regarding classification, diagnosis, and management of HA.
While HAs are typically considered benign, complications such as hemorrhage and malignant transformation may occur in approximately 25% and 5% of patients, respectively. Recent advances in imaging and molecular profiling have allowed for the classification of HAs into subtypes allowing for patient risk stratification that helps guide management. Surgical resection should be considered in asymptomatic patients who are male, have an adenoma ≥5 cm in diameter, or have the β-catenin-activated subtype due to an increased risk of hemorrhage and/or malignant transformation.
Molecular profiling has aided in the stratification of patients relative to the risk of complications to predict better the potential behavior of HAs.
摘要：
肝腺瘤(HA),或肝细胞腺瘤，是良性的，在其他正常肝脏中发展的实体肝脏病变，通常在雌激素水平升高的情况下。虽然被认为是良性肿瘤，有大量并发症的风险,如出血和恶性转化.我们检查诊断结果,分类，以及HA患者的潜在治疗管理选择。
根据最近关于分类的文献进行了范围界定叙事综述，诊断,和HA的管理。
虽然HAs通常被认为是良性的，并发症，如出血和恶变可能发生在大约25％和5％的患者，分别。影像学和分子谱分析的最新进展已允许将HAs分类为亚型，从而允许对患者进行风险分层，以帮助指导管理。男性无症状患者应考虑手术切除，腺瘤直径≥5cm,或由于出血和/或恶性转化的风险增加而具有β-连环蛋白激活的亚型。
分子谱分析有助于患者相对于并发症风险的分层，以更好地预测HA的潜在行为。
根据最近关于分类的文献进行了范围界定叙事综述，诊断,和HA的管理。
虽然HAs通常被认为是良性的，并发症，如出血和恶变可能发生在大约25％和5％的患者，分别。影像学和分子谱分析的最新进展已允许将HAs分类为亚型，从而允许对患者进行风险分层，以帮助指导管理。男性无症状患者应考虑手术切除，腺瘤直径≥5cm,或由于出血和/或恶性转化的风险增加而具有β-连环蛋白激活的亚型。
分子谱分析有助于患者相对于并发症风险的分层，以更好地预测HA的潜在行为。
